Gossamer Bio (GOSS) reprices Chief Medical Officer stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Gossamer Bio, Inc. reported that Chief Medical Officer Richard Aranda had a one-time repricing of certain outstanding stock options effective March 19, 2026. A series of existing options were surrendered back to the company and replaced with new options covering the same numbers of shares, but with a reduced exercise price of $0.45 per share.
According to the disclosure, all other terms and conditions of the repriced options, including vesting schedules and expiration dates under the 2019 Incentive Award Plan, remain unchanged and continue to depend on his ongoing service with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
24 transactions reported
Mixed
24 txns
Insider
Aranda Richard
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 562,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 572,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 487,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 162,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 157,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 157,500 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 126,667 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 20,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 40,000 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 22,784 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 9,167 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 30,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 562,500 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 572,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 487,500 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 162,500 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 157,500 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 157,500 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 126,667 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 20,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 40,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 22,784 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 9,167 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 30,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct)
Footnotes (1)
- Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
FAQ
What did the GOSS Form 4 filing disclose about Richard Aranda’s options?
The filing shows Chief Medical Officer Richard Aranda exchanged existing stock options for new ones with a lower exercise price of $0.45 per share. The number of options and all other terms, including vesting and expiration, remain the same under the 2019 Incentive Award Plan.
Was this a new stock option grant for Gossamer Bio (GOSS) CMO Aranda?
The transactions reflect a repricing rather than an entirely new award. Existing options were returned to the issuer and reissued at a reduced $0.45 exercise price, while keeping prior share amounts, vesting provisions, and expiration dates intact under the 2019 Incentive Award Plan.
How were Gossamer Bio CMO Richard Aranda’s stock options repriced?
On March 19, 2026, certain outstanding options were cancelled and replaced with options for the same number of underlying common shares at a new $0.45 exercise price. Footnotes state that vesting terms and option durations otherwise remain in full force and effect.
Did the GOSS Form 4 indicate any open-market stock sales or purchases?
No open-market trades were reported. The Form 4 lists dispositions to the issuer of existing stock options and corresponding acquisitions of repriced options. These are compensation-related adjustments rather than market purchases or sales of Gossamer Bio common stock.
What role does Gossamer Bio’s 2019 Incentive Award Plan play in this Form 4?
All affected stock options were granted under the 2019 Incentive Award Plan. The repricing only reduced each option’s exercise price to $0.45 per share, while leaving vesting schedules, term provisions, and service-based conditions from the original plan awards unchanged.
Are the repriced GOSS stock options subject to continued service requirements?
Yes. A footnote explains that the stock option award remains exercisable according to its existing vesting schedule, which is conditioned on Richard Aranda’s continued service with Gossamer Bio as of each applicable vesting date specified in the award agreement.